PDF(Pubmed)
Abstract：
OBJECTIVE: Examining the distribution of breast cancer (BC) stage and molecular subtype among women aged below (< 45 years), within (45-65 years), and above (> 65 years) the recommended screening age range helps to understand the screening program\'s characteristics and contributes to enhancing the effectiveness of BC screening programs.
METHODS: In this retrospective study, female patients with newly diagnosed BC from 2010 to 2020 were identified. The distribution of cases in terms of TNM stages, severity classes, and subtypes was analysed according to age groups.
RESULTS: A total of 3282 women diagnosed with BC were included in the analysis. Among these cases 51.4% were detected outside the screening age group, and these were characterized by a higher TNM stage compared to those diagnosed within the screening age band. We observed significantly higher relative frequency of advanced BC in the older age group compared to both the screening age population and women younger than 45 years (14.9% vs. 8.7% and 7.7%, P < 0.001). HR-/HER2- and HER+ tumours were relatively more frequent among women under age 45 years (HR-/HER2-: 23.6%, HER2+: 20.5%) compared to those within the screening age range (HR-/HER2-: 13.4%, HER2+: 13.9%) and the older age group (HR-/HER2-: 10.4%, HER2+: 11.5%).
CONCLUSIONS: The findings of our study shed light on potential areas for the improvement of BC screening programs (e.g., extending screening age group, adjusting screening frequency based on molecular subtype risk status) in Hungary and internationally, as well.
METHODS: In this retrospective study, female patients with newly diagnosed BC from 2010 to 2020 were identified. The distribution of cases in terms of TNM stages, severity classes, and subtypes was analysed according to age groups.
RESULTS: A total of 3282 women diagnosed with BC were included in the analysis. Among these cases 51.4% were detected outside the screening age group, and these were characterized by a higher TNM stage compared to those diagnosed within the screening age band. We observed significantly higher relative frequency of advanced BC in the older age group compared to both the screening age population and women younger than 45 years (14.9% vs. 8.7% and 7.7%, P < 0.001). HR-/HER2- and HER+ tumours were relatively more frequent among women under age 45 years (HR-/HER2-: 23.6%, HER2+: 20.5%) compared to those within the screening age range (HR-/HER2-: 13.4%, HER2+: 13.9%) and the older age group (HR-/HER2-: 10.4%, HER2+: 11.5%).
CONCLUSIONS: The findings of our study shed light on potential areas for the improvement of BC screening programs (e.g., extending screening age group, adjusting screening frequency based on molecular subtype risk status) in Hungary and internationally, as well.
摘要：
目的：检查乳腺癌（BC）分期和分子亚型在年龄以下（<45岁）女性中的分布，在（45-65岁）推荐的筛查年龄范围(>65岁)有助于了解筛查方案的特点,并有助于提高BC筛查方案的有效性.
方法：在这项回顾性研究中，纳入2010年至2020年新诊断的女性BC患者.按TNM分期划分的病例分布情况,严重性等级,根据年龄组分析亚型。
结果：共有3282名被诊断为BC的妇女被纳入分析。在这些病例中，51.4%是在筛查年龄组之外检测到的，与筛查年龄段内诊断的患者相比，这些患者的TNM分期更高。我们观察到，与筛查年龄人群和45岁以下女性相比，老年组的晚期BC相对频率明显更高（14.9％vs.8.7%和7.7%，P<0.001)。在45岁以下的女性中，HR-/HER2-和HER+肿瘤相对更常见（HR-/HER2-：23.6%，HER2+：20.5%）与筛查年龄范围内的人群（HR-/HER2-：13.4%，HER2+：13.9%）和老年组（HR-/HER2-：10.4%，HER2+：11.5%）。
结论：我们的研究结果揭示了改善BC筛查计划的潜在领域（例如，延长筛查年龄组，根据分子亚型风险状况调整筛查频率)在匈牙利和国际上，也是。
方法：在这项回顾性研究中，纳入2010年至2020年新诊断的女性BC患者.按TNM分期划分的病例分布情况,严重性等级,根据年龄组分析亚型。
结果：共有3282名被诊断为BC的妇女被纳入分析。在这些病例中，51.4%是在筛查年龄组之外检测到的，与筛查年龄段内诊断的患者相比，这些患者的TNM分期更高。我们观察到，与筛查年龄人群和45岁以下女性相比，老年组的晚期BC相对频率明显更高（14.9％vs.8.7%和7.7%，P<0.001)。在45岁以下的女性中，HR-/HER2-和HER+肿瘤相对更常见（HR-/HER2-：23.6%，HER2+：20.5%）与筛查年龄范围内的人群（HR-/HER2-：13.4%，HER2+：13.9%）和老年组（HR-/HER2-：10.4%，HER2+：11.5%）。
结论：我们的研究结果揭示了改善BC筛查计划的潜在领域（例如，延长筛查年龄组，根据分子亚型风险状况调整筛查频率)在匈牙利和国际上，也是。
